Similar articles for PMID: 33741645

Year	Number of Results
1969	1
1975	2
1981	1
1983	1
1984	1
1985	1
1987	1
1992	1
1993	3
1994	5
1995	2
1996	3
1997	2
1998	1
1999	3
2000	1
2001	1
2002	3
2003	5
2004	2
2005	2
2006	3
2007	2
2008	1
2009	5
2010	4
2011	2
2012	3
2013	5
2014	7
2015	8
2016	2
2017	4
2018	3
2019	7
2020	5
2021	5
2024	0

1

Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy.

Wee CE, Dundar A, Eiring RA, Badawy M, Hobday TJ, Kendi AT, Packard AT, Halfdanarson TR. Wee CE, et al. J Nucl Med. 2021 Sep 1;62(9):1320. doi: 10.2967/jnumed.121.262048. Epub 2021 Mar 19. J Nucl Med. 2021. PMID: 33741645 Free article. No abstract available.

2

Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy.

Strosberg JR, Al-Toubah T, El-Haddad G. Strosberg JR, et al. J Nucl Med. 2021 Sep 1;62(9):1321. doi: 10.2967/jnumed.121.262340. Epub 2021 Jul 8. J Nucl Med. 2021. PMID: 34244354 Free article. No abstract available.

3

Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy.

Strosberg JR, Al-Toubah T, Pellè E, Smith J, Haider M, Hutchinson T, Fleming JB, El-Haddad G. Strosberg JR, et al. J Nucl Med. 2021 Jan;62(1):69-72. doi: 10.2967/jnumed.120.242875. Epub 2020 May 22. J Nucl Med. 2021. PMID: 32444368 Free article.

4

Radiological imaging change in a malignant bowel obstruction patient treated with octreotide.

Shinjo T, Kagami R. Shinjo T, et al. Support Care Cancer. 2009 Jun;17(6):753-5. doi: 10.1007/s00520-009-0608-4. Epub 2009 Mar 11. Support Care Cancer. 2009. PMID: 19277723

5

Hepatic portal venous gas: a rare complication of malignant bowel obstruction during the administration of octreotide.

Maeda I, Tsuneto S, Yasui Y, Ueda Y, Kimura T. Maeda I, et al. J Pain Symptom Manage. 2014 Feb;47(2):e2-5. doi: 10.1016/j.jpainsymman.2013.10.014. Epub 2013 Dec 31. J Pain Symptom Manage. 2014. PMID: 24388125 Free article. No abstract available.

6

Octreotide for malignant bowel obstruction: twenty years after.

Mercadante S, Porzio G. Mercadante S, et al. Crit Rev Oncol Hematol. 2012 Sep;83(3):388-92. doi: 10.1016/j.critrevonc.2011.12.006. Epub 2012 Jan 25. Crit Rev Oncol Hematol. 2012. PMID: 22277783 Review.

7

Octreotide may prevent definitive intestinal obstruction.

Mercadante S, Kargar J, Nicolosi G. Mercadante S, et al. J Pain Symptom Manage. 1997 Jun;13(6):352-5. doi: 10.1016/s0885-3924(97)00084-5. J Pain Symptom Manage. 1997. PMID: 9204656 Free article.

8

Octreotide in malignant intestinal obstruction.

Pandha HS, Waxman J. Pandha HS, et al. Anticancer Drugs. 1996 Jan;7 Suppl 1:5-10. doi: 10.1097/00001813-199601001-00002. Anticancer Drugs. 1996. PMID: 8822079 Review.

9

Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.

Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Mercadante S, et al. Support Care Cancer. 2000 May;8(3):188-91. doi: 10.1007/s005200050283. Support Care Cancer. 2000. PMID: 10789958 Clinical Trial.

10

Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.

Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, Paganelli G. Bodei L, et al. Thorac Surg Clin. 2014 Aug;24(3):333-49. doi: 10.1016/j.thorsurg.2014.04.005. Epub 2014 Jun 9. Thorac Surg Clin. 2014. PMID: 25065935 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

97 results

Results by year